| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Profound Medical Corp.$7.04
-0.29 (-3.96%)
F 13Pipeline Score MedTech · Commercial
Market Cap
248.19 M
EPS
-1.24
P/E Ratio
-
Value Trade
259.84 K
SEC Financials
Q1 2026Dilution Risk
35%Revenue
5.34 M
R&D Expenses
5.26 M
Operating CF
-8.58 M
Total Assets
73.46 M
Total Liabilities
14.03 M
Equity
59.42 M
D/E Ratio
12,345
-5.66 %
Week
-0.58 %
1 Month
-1.3 %
3 Month
15.18 %
6 Month
-64.01 %
5 Year
-32.94 %
All Time
Cash Data
Cash Position
50.30 M
Monthly Burn
2.86 M
Runway
15.7 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
61.46 K
52 Week Range
3.76 - 8.95
% held by Insiders
2.97 %
% held by Institutions
45.44 %
Enterprise Value
205.21 M
Total Shares
36.34 M
Short %
5.9 %
Float Shares
35.08 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 9%
Micro Cap (rank 830 of 911)
Percentile RankProfound Medical Corp. has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TULSA Procedure | localized prostate cancer | — | 2026-03-13 | preservation of function: both function 50%, continence 84%, erectile function 56%; robotic rp results: both function 24%, continence 49%, erectile function 47%; perioperative measures: blood loss 0 mL, hospital stay 0.3 days, days off work 10 days Read More | CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence Read More | |
TULSA Procedure | localized prostate cancer | — | 2026-03-13 | preservation of function: both function 50%, continence 84%, erectile function 56%; robotic rp results: both function 24%, continence 49%, erectile function 47%; perioperative measures: blood loss 0 mL, hospital stay 0.3 days, days off work 10 days Read More | CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence Read More | |
TULSA Procedure | localized prostate cancer | — | 2026-03-13 | preservation of function: both function 50%, continence 84%, erectile function 56%; robotic rp results: both function 24%, continence 49%, erectile function 47%; perioperative measures: blood loss 0 mL, hospital stay 0.3 days, days off work 10 days Read More | CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PROF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PROF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PROFProfound to Showcase TULSA-PRO , the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Corp. is set to showcase the TULSA Procedure™ at the upcoming AUA2026 annual meeting, with several presentations planned by noted physicians. The company will demonstrate the TULSA-PRO® system and highlight the potential integration of PSMA PET imaging to improve treatment planning for prostate cancer. Experts will discuss the effectiveness of the procedure in addressing localized prostate cancer and the benefits of personalized treatment. This emphasis on innovative imaging and treatment strategies positions Profound as a leader in the emerging field of MRI-guided therapies.
Read more →PROFProfound Medical Reports Strong First Quarter 2026 Financial Results
Profound Medical Corp. reported impressive financial results for Q1 2026, showcasing a 104% increase in revenue year-over-year. The company's TULSA Procedure has gained coverage from Humana, enhancing access for many patients. Profound anticipates the full-year 2026 revenue to reach around $25 million, marking a 56% increase from the previous year. Despite these positives, the company still faces challenges in accurately predicting short-term revenues and recorded a net loss of approximately $7 million for the quarter.
Read more →PROFProfound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Profound Medical Corp. will announce its first quarter 2026 financial results on May 7, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. Profound specializes in AI-powered, MRI-guided therapies for tissue ablation, enhancing patient outcomes and procedural control.
Read more →PROFProfound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present an update on its business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026. The presentation will highlight the company's advancements in AI-powered, MRI-guided therapies for treating various prostate conditions and other medical applications. Profound's technologies aim to improve clinical outcomes while minimizing side effects associated with traditional surgical methods.
Read more →PROFProfound Medical Corp. Investigated by the Portnoy Law Firm
Profound Medical Corp. is currently under investigation by the Portnoy Law Firm for potential securities fraud. The inquiry comes after the company admitted to an error that overstated its revenue by $472,000 in Q1 2024. As a result of this disclosure, the company's stock price dropped by 5.9%, leading to concerns among investors. The firm is offering complimentary case evaluations to affected investors as they consider pursuing class-action claims.
Read more →PROFIncision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Profound Medical Corp. will showcase its TULSA-PRO system at the 2026 Society of Interventional Radiology Annual Scientific Meeting. The TULSA Procedure, which utilizes MRI-guided, incision-free technology, aims to treat prostate cancer and benign prostatic hyperplasia effectively. Presentations will highlight its clinical outcomes and innovative approaches to prostate care.
Read more →PROFProfound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Profound Medical Corp. announced that Texas Prostate has successfully completed its 100th TULSA Procedure at the Dallas Medical Center. This innovative procedure utilizes MRI guidance to treat various prostate conditions with improved safety and precision. Following a shift to a Medicare model, the number of procedures performed has surged by 500%, indicating strong demand and adoption among urologists in the region.
Read more →PROFCAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
The CAPTAIN trial demonstrated that the TULSA Procedure significantly outperforms robotic radical prostatectomy in preserving erectile function and urinary continence at six months post-treatment. With a successful enrollment of 211 patients, the trial met its primary safety endpoint, showing a marked improvement in quality of life outcomes. The results suggest that TULSA could become a standard treatment for localized prostate cancer.
Read more →PROFProfound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Profound Medical Corp. will present the first clinical outcomes from the CAPTAIN trial at the EAU 2026 Congress on March 13, 2026. The trial compares the TULSA Procedure with robotic radical prostatectomy for localized prostate cancer. Following the presentation, an investor webinar will discuss the clinical data and its implications for prostate cancer treatment guidelines. Additionally, Profound will participate in the ROTH Conference from March 22-24, 2026.
Read more →PROFProfound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Profound Medical Corp. reported strong financial results for Q4 and the full year of 2025, achieving record revenues driven by a growing TULSA-PRO sales pipeline. The company anticipates increasing its installed base to about 120 by the end of 2026. Despite these successes, Profound experienced a net loss of $8.2 million for Q4 2025, reflecting rising operating expenses and decreased gross margins. Looking ahead, upcoming clinical trial results may influence future growth and profitability.
Read more →PROFProfound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
Profound Medical Corp. has been awarded the 2025/2026 Mount Logan Award by INOVAIT for its innovative TULSA Procedure, which has treated over 4,000 patients. The award recognizes the company's achievements in interventional MRI and its efforts to expand patient access globally. The TULSA Procedure offers a precise and minimally invasive treatment for prostate conditions, enhancing patient recovery and reducing side effects.
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
Profound Medical Corp. (NASDAQ: PROF) will announce its fourth quarter and full year 2025 financial results after market close on March 5, 2026. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss the results and relevant business developments. The company specializes in interventional MRI procedures, specifically the TULSA-PRO system, which shows promise for treating various prostate-related conditions.
Read more →PROF▼ -7.3%on this news
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Profound Medical Corp. announced that PRO FAMILIA Specialist Hospital in Poland has completed its 500th Sonalleve procedure, providing women with a non-invasive treatment for gynecologic conditions. The MRI-guided therapy offers targeted relief without incisions, reducing complications and preserving fertility. The technology is gaining traction internationally, with over 4,000 women treated so far.
Read more →PROFProfound Medical Announces Upcoming Investor Events
Profound Medical Corp. has announced its participation in upcoming investor events in February. The company specializes in AI-powered, MRI-guided therapies for tissue ablation, including the TULSA-PRO system for prostate treatment and Sonalleve for uterine fibroids. Both technologies are CE marked and have received various regulatory approvals, highlighting their market readiness.
Read more →PROF▲ +9.4%on this news
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Mount Sinai Hospital has become the first in Metro New York to perform the TULSA Procedure, an AI-powered, MRI-guided treatment for prostate cancer. This innovative therapy allows for precise ablation of prostate tissue without incisions, minimizing recovery time and side effects. The procedure was successfully completed on a patient who was discharged the same day.
Read more →PROFProfound Surpasses 2025 TULSA-PRO Installed Base Goal
Profound Medical Corp. has exceeded its 2025 goal for the TULSA-PRO installed base, reaching 78 units. The company's sales pipeline for the TULSA-PRO has also grown, with 97 systems in various stages of negotiation. CEO Arun Menawat highlighted that this growth could lead to increased patient treatment rates and higher recurring revenues. Profound will disclose its fourth quarter and yearly financial results later in February 2026.
Read more →PROFProfound Medical Corp. Announces Closing of Private Placement TORONTO
Profound Medical Corp. has announced the successful completion of its private placement, raising approximately $6.45 million by issuing 921,428 common shares at a price of $7.00 each. The company plans to utilize the proceeds for sales and marketing expansion, working capital, and research and development initiatives. The common shares are subject to a holding period under Canadian securities laws. Profound Medical continues to advance its innovative treatment technologies, including TULSA-PRO, aimed at improving patient outcomes in prostate disease treatment.
Read more →PROFProfound Medical Corp. Announces Upsize of Private Placement
Profound Medical Corp. has announced an upsize of its private placement, increasing the total proceeds to a maximum of $6.45 million through the sale of up to 921,428 common shares at $7.00 each. This move is aimed at accommodating a long-term investor and will help fund the company's expansion in sales, marketing, and research. The offering will not be available to U.S. purchasers and is anticipated to close by December 30, 2025.
Read more →PROFProfound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Profound Medical Corp. announced the closing of a registered direct offering, raising approximately $36 million by selling 5,142,870 common shares at $7.00 each. The company intends to utilize the net proceeds for various initiatives, including expansion of marketing, working capital, and research and development. Moreover, Profound plans to execute a private placement for certain Canadian purchasers before December 30, 2025. The offering was facilitated by Konik Capital Partners, and the announcement is part of Profound's strategy to enhance its operational capabilities.
Read more →PROFProfound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Profound Medical Corp. has announced a financing plan to raise up to $40 million through a registered direct offering and a private placement. The registered direct offering will involve the sale of over 5 million common shares at $7.00 each, expected to close by December 22, 2025. The funds will be allocated towards expanding sales, marketing, and R&D efforts.
Read more →PROFProfound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Profound Medical Corp. is set to launch its TULSA-AI Volume Reduction module for treating benign prostatic hyperplasia (BPH) at the upcoming RSNA meeting. This AI-powered technology aims to enhance treatment efficiency and patient outcomes. Additionally, new clinical data on the TULSA-PRO system for prostate cancer will be presented at both RSNA and SUO meetings, highlighting its advantages over traditional procedures.
Read more →PROFProfound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Profound Medical Corp. announced that The Hong Center Scottsdale has achieved a significant milestone by performing 200 independent TULSA Procedures for prostate disease. The TULSA Procedure, which uses AI-powered, MRI-guided technology, allows urologists to ablate prostate tissue without surgical intervention or radiation. Dr. Y. Mark Hong's pioneering work highlights the potential of TULSA as a transformative treatment option for prostate cancer, demonstrating safe and effective outcomes for a wide range of patients. This achievement not only solidifies Dr. Hong's role in advancing prostate care but also showcases the efficacy of Profound's innovative medical technologies.
Read more →PROFشركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية
Profound Medical has announced a significant exclusive distribution agreement with Al Faisaliah Medical Systems in Saudi Arabia for its TULSA-PRO and Sonalleve products. This partnership aims to expand the market presence of Profound's advanced non-invasive treatment technologies for prostate diseases. The agreement is expected to enhance access to these innovative medical solutions in the region.
Read more →PROFProfound Medical Reports Strong Third Quarter 2025 Financial Results
Profound Medical Corp. reported strong third-quarter financial results for 2025, with revenue reaching $5.3 million, a significant 87% increase from the previous year. The company's gross margin improved to 74.3%, reflecting operational efficiencies. Additionally, the TULSA-PRO installed base is expanding, and Profound is establishing strategic partnerships to enhance distribution capabilities. However, the company's operating expenses rose, leading to a net loss of $8.0 million for the quarter, though this represented an improvement from the prior year.
Read more →PROFProfound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Profound Medical Corp. has secured an exclusive distribution agreement with Getz Healthcare to introduce its TULSA-PRO system in Australia and New Zealand. This AI-powered, MRI-guided technology offers a minimally invasive alternative for prostate treatment. The partnership aims to enhance precision prostate care in the region, addressing the high incidence of prostate cancer among men.
Read more →PROFProfound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Profound Medical Corp. has signed an exclusive distribution agreement with Al Faisaliah Medical Systems to market its TULSA-PRO and Sonalleve technologies in Saudi Arabia. This partnership aims to enhance the availability of incision-free and radiation-free therapies for treating diseased tissue in the region. Regulatory approvals for both technologies are already secured, positioning Profound for growth in the Middle East's healthcare market.
Read more →PROF▲ +7.3%on this newsshared move
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO system in Canada from Knight Therapeutics. This system is designed for the ablation of prostate tissue in patients with prostate cancer or benign prostatic hyperplasia. The agreement includes a one-time payment and a royalty on sales. Profound aims to expand the TULSA Procedure's availability in Canada, leveraging clinical trial results for insurance coverage applications.
Read more →PROFProfound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
Profound Medical Corp. announced that the Busch Center has successfully completed its 500th TULSA Procedure, showcasing the treatment's effectiveness for a range of prostate diseases. Dr. Joseph Busch highlighted the procedure's success in complicated cases, with minimal side effects such as urinary incontinence. The TULSA Procedure is recognized for its precision and customization, making it a promising option for patients with prostate cancer and benign prostatic hyperplasia.
Read more →PROFProfound Medical to Participate in the Stifel 2025 Healthcare Conference
Profound Medical Corp. will present at the Stifel 2025 Healthcare Conference on November 11, 2025. The company focuses on AI-powered, incision-free therapies for tissue ablation, including the TULSA Procedure for prostate conditions. Their technologies are CE marked and FDA cleared, with ongoing exploration of new treatment markets.
Read more →PROF▲ +11.8%on this news
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
Profound Medical Corp. announced preliminary unaudited revenues for Q3 2025, estimating between $5.2 million and $5.3 million, marking a significant growth of 84-87% year-over-year. The gross margin is expected to rise to 72%. CEO Arun Menawat highlighted the growth in TULSA-PRO installations and utilization. Full financial results will be disclosed on November 13, 2025.
Read more →PROF▲ +17.7%on this news
Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
Profound Medical Corp. has launched a pioneering TULSA program in collaboration with Texas Prostate and Dallas Medical Center to enhance access to advanced prostate treatments without surgery. This initiative, now covered by Medicare, allows for the TULSA Procedure to be performed in a state-of-the-art MRI suite, offering patients a less invasive option with fewer side effects. The TULSA Procedure utilizes AI-powered technology for precise tissue ablation, marking a significant advancement in prostate care.
Read more →PROFProfound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference
Profound Medical Corp. will participate in the Lake Street Capital Markets 'BIG9' Conference on September 11, 2025, in New York City. The event will feature one-on-one investor meetings, although no webcast will be available. Profound is known for its incision-free therapies for prostate disease, including the TULSA-PRO® system and Sonalleve® platform.
Read more →PROF▼ -23.3%on this news
Profound Medical Announces Second Quarter 2025 Financial Results
Profound Medical Corp. reported its second quarter 2025 financial results, showing revenues of approximately $2.2 million, unchanged from the previous year. The company faced delays in TULSA-PRO capital sales, which could have increased revenues by over $3 million. Despite a gross margin increase to 73%, net losses rose to $15.7 million, attributed to higher operating expenses. The company maintains a strong cash position of $35.2 million.
Read more →PROFProfound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow
Profound Medical Corp. will announce its second quarter 2025 financial results on August 14, 2025, followed by a conference call to discuss the results and business developments. The company specializes in customizable, incision-free therapies for tissue ablation, notably through its TULSA-PRO system for treating prostate conditions. The device combines advanced imaging and AI technologies for precision treatment with quick recovery times. Profound is also working on its Sonalleve platform for treating uterine fibroids and palliative pain.
Read more →PROF▲ +17.4%on this news
Profound Medical Announces First Commercial BPH Patient Treatment Using TULSA-PRO with TULSA-AI Volume Reduction
Profound Medical Corp. has successfully conducted the first commercial treatment for benign prostatic hyperplasia (BPH) utilizing the TULSA-PRO system with the new TULSA-AI Volume Reduction Module. This advancement is expected to streamline procedures, reduce treatment times, and enhance patient recovery experiences. Recent studies highlight significant improvements in urinary function and quality of life, indicating the system's potential in the treatment of BPH. Despite challenges in patient volume previously, the new technology aims to expand market opportunities significantly.
Read more →PROF▼ -5.4%on this news· ran to +17% by day 3
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Profound Medical Corp. held its Annual General and Special Meeting of Shareholders on May 14, 2025, where significant voting results were announced. Shareholders approved all resolutions, including the election of six board nominees and the appointment of PricewaterhouseCoopers LLP as auditor. A total of 20,587,011 common shares, representing 68.5% of shares outstanding, were represented at the meeting. Detailed voting results will be posted under the company's profile on SEDAR.
Read more →PROFProfound Medical Announces First Quarter 2025 Financial Results
Profound Medical Corp. reported unaudited financial results for Q1 2025, revealing an impressive 82% revenue growth, reaching approximately $2.6 million. The company highlighted successful treatments using its TULSA-PRO technology for various prostate disease patients and positive feedback from AUA 2025. Despite a rise in operating expenses and an increased net loss of $10.7 million, the company maintains a strong gross margin and cash position. Profound continues to position its innovative solutions as potential standards of care in prostate treatments.
Read more →PROFProfound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 6, 2025. The presentation will provide updates on the company's business and its innovative, incision-free therapies for tissue ablation. This event highlights the company's commitment to investor engagement and transparency.
Read more →PROFProfound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present an update on its business at the 2025 Bloom Burton & Co. Healthcare Investor Conference, scheduled for May 6, 2025. The presentation will occur at the Metro Toronto Convention Centre and will be accessible via a live broadcast on the company's website. Profound Medical focuses on developing incision-free therapies, including the TULSA-PRO and Sonalleve platforms for treating prostate conditions and uterine fibroids, respectively.
Read more →PROFInitial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
The CAPTAIN randomized trial has revealed that MRI-guided TULSA significantly enhances the post-operative experience compared to robotic radical prostatectomy. This initial perioperative data suggests a promising alternative for patients undergoing prostate surgery. Profound Medical Corp. is at the forefront of this innovative approach.
Read more →PROFEstablishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer CAPTAIN Level 1 randomized c
The CAPTAIN randomized trial compares TULSA-PRO with robotic prostatectomy for localized prostate cancer treatment. Results indicate that TULSA-PRO offers improved peri-operative outcomes, including no blood loss and less post-procedure pain. Patients reported quicker recovery times and higher satisfaction levels with TULSA-PRO. This study establishes TULSA as a viable treatment option, likely influencing its adoption in clinical practice.
Read more →PROFProfound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow
Profound Medical Corp. is scheduled to announce its first quarter 2025 financial results on May 8, 2025. Following the release, management will hold a conference call to discuss the results and related business developments. The company specializes in incision-free therapies for diseased tissue, highlighting active advancements with its TULSA-PRO system and Sonalleve platform. Both technologies are CE marked and approved by regulatory bodies in various regions, showcasing the company's commitment to innovative treatments.
Read more →PROFProfound Medical AUA 2025 Investor Event Agenda
Profound Medical Corp. has announced additional details for its hybrid investor event scheduled for April 28, 2025, during the AUA's Annual Meeting in Las Vegas. The event will showcase presentations from management and leading physicians, emphasizing the innovative TULSA-PRO® system for treating prostate conditions. This includes updates on the efficacy of TULSA in comparison to traditional treatments and insights into future programs, specifically targeting benign prostatic hyperplasia and further enhancements in prostate cancer care. A live webcast will also be made available for those unable to attend in person.
Read more →PROFSave the Date: Profound Medical to Host Investor Event at AUA 2025
Profound Medical Corp. will host a hybrid investor event on April 28, 2025, during the AUA Annual Meeting in Las Vegas. The event aims to engage investors and highlight the company's innovative therapies for tissue ablation. It will take place from 3:30 p.m. to 5:00 p.m. Pacific Time.
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2024 Financial Results
Profound Medical Corp. reported significant financial growth for Q4 and the full year 2024, highlighting a 108% revenue increase year-over-year. The company made strategic executive changes and announced a collaboration with Siemens Healthineers to enhance the TULSA procedure's accessibility. Despite the positive financial results, Profound faced challenges with rising operating expenses and a substantial net loss. Additionally, the company identified a revenue overstatement error that necessitates revising past financial statements.
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
Profound Medical Corp. will announce its fourth quarter and full year 2024 financial results on March 6, 2025. Following the announcement, management will host a conference call to discuss the results and business developments. The company focuses on customizable, incision-free therapies, including their TULSA-PRO® system for prostate treatments and Sonalleve® for uterine fibroids, indicating a strong positioning within the medical device market.
Read more →PROFUpdate: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th
Profound Medical Corp. has announced a change in the timing of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The new presentation time is set for 9:00 a.m. Pacific Time on January 16, 2025. This event highlights the company's ongoing efforts in developing incision-free therapies for tissue ablation.
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
Profound Medical Corp. (NASDAQ: PROF) has announced its preliminary unaudited revenue estimates for the fourth quarter and full year of 2024, projecting a growth of 105% to 110% year-over-year. The company expects fourth quarter revenues to be around $4.1 million to $4.2 million, contributing to an estimated total of $11.1 million to $11.2 million for the full year. Starting January 1, 2025, Profound will report financial results in accordance with U.S. GAAP, which aims to improve accessibility for U.S.-based investors. The CEO noted the growing adoption of their TULSA-PRO® technology and emphasized that the company is now poised for escalating growth following a recent public offering.
Read more →PROFProfound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Profound Medical Corp. has announced that it will present its business updates at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will be accessible via live stream on the company’s website. Profound specializes in incision-free therapies for tissue ablation, notably through its TULSA-PRO® system and Sonalleve® platform, both of which have received various regulatory approvals for treatment applications. This event further signifies the company’s ongoing efforts in expanding its visibility and market reach in the medical device sector.
Read more →PROFProfound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares
Profound Medical Corp. has successfully completed an underwritten public offering of common shares, raising approximately $40.25 million. The offering saw the exercise of the over-allotment option in full, resulting in the issuance of over 5.3 million shares at a price of $7.50 each. The funds raised will support the commercialization and development of their medical technologies, TULSA-PRO and Sonalleve, as well as contribute to working capital and other corporate purposes. This indicates a positive response from investors toward the company's future prospects.
Read more →PROF▼ -6.7%on this newsshared move
Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares
Profound Medical Corp. has announced the pricing of an underwritten public offering of 4,666,700 common shares at US$7.50 each, aiming to raise approximately US$35 million. The proceeds will be utilized for the ongoing commercialization and development of their TULSA-PRO® system in the U.S. and globally, along with general corporate purposes. The offering is expected to close on December 10, 2024, subject to customary closing conditions including necessary approvals. This initiative reflects Profound's commitment to advancing its medical technology offerings.
Read more →PROF▼ -6.7%on this newsshared move
FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (" Profound " or the " Company ") Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change
Profound Medical Corp. announced the successful pricing of an underwritten public offering of 4,666,700 common shares at $7.50 each, raising approximately US$40.25 million. The proceeds will be used to support the commercialization of the TULSA-PRO system in the U.S. and the global development of both TULSA-PRO and Sonalleve systems. The offering closed on December 10, 2024, with the Over-Allotment Option fully exercised. Additionally, a related party transaction involved the Chief Commercial Officer purchasing shares, which was approved by the Board and deemed exempt from certain valuation requirements.
Read more →PROF▼ -6.7%on this newsshared move
Execution Version PROFOUND MEDICAL CORP. 4,666,700 Common Shares
Profound Medical Corp. has announced an underwriting agreement for 4,666,700 common shares with several underwriters, including Raymond James and Lake Street Capital Markets. The company has filed a short form base shelf prospectus qualifying the distribution of up to $150 million in various securities. This arrangement positions the company favorably for potential capital raising activities in the forthcoming year.
Read more →PROFBay Street, South Tower Suite 2800 Toronto, ON 647 499 2828 mintz.com
Profound Medical Corp. has filed a registration statement on Form F-10, which includes a prospectus requiring certain legal consents. The firm Mintz LLP has consented to the reference of their name within this document. Importantly, this consent does not indicate that Mintz LLP considers itself to be within the category of persons requiring consent under the Securities Act of 1933. The statement emphasizes the legal implications surrounding the consent process in relation to the registration statement.
Read more →PROFProfound Medical Announces Proposed Public Offering of Common Shares
Profound Medical Corp. announced a proposed public offering of common shares intended to raise capital for the commercialization of its TULSA-PRO® and Sonalleve® systems. The offering will also provide funds for general corporate purposes. It involves an underwritten process with a 30-day option for underwriters to purchase additional shares, depending on market conditions. The offering aims to close around December 10, 2024, following necessary regulatory approvals.
Read more →PROFProfound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
Profound Medical has entered into a co-sales and marketing agreement with Siemens Healthineers to promote an MRI-guided prostate therapy solution utilizing Profound's TULSA-PRO system alongside Siemens' Magnetom Free.Max scanner. This partnership aims to enhance the treatment options available for prostate disease patients while ensuring compliance with the new U.S. Medicare reimbursement model effective January 2025. The TULSA procedure is noted for being incision-free and designed to maintain urinary and sexual function during treatment, promising a wide range of applications across various service locations.
Read more →PROFProfound Medical to Unveil Next TULSA-AI Module, ‘UA Alignment Assistant’
Profound Medical Corp. (NASDAQ:PROF) is set to unveil its third TULSA-AI module, the UA Alignment Assistant, at the upcoming RSNA 2024 and SUO 2024 meetings. This software aims to streamline the alignment process for the ultrasound applicator used during the TULSA procedure, potentially improving workflow consistency for clinicians. The TULSA procedure offers a non-invasive treatment for a variety of prostate conditions, which may lead to broader adoption. Additionally, several presentations on TULSA's efficacy will be featured at the conferences, underscoring its clinical relevance and innovation.
Read more →PROFProfound Medical to Participate in the Stifel 2024 Healthcare Conference
Profound Medical Corp. has announced its participation in the Stifel 2024 Healthcare Conference, where it will provide an update on its business operations. The conference is scheduled for November 19, 2024, in NYC, and the presentation will be broadcast live on the company's website. Profound Medical focuses on developing incision-free therapies, notably the TULSA-PRO® for prostate treatments and Sonalleve® for uterine fibroids and bone metastases.
Read more →PROF▲ +12%on this newsshared move
Profound Medical Announces Third Quarter 2024 Financial Results
Profound Medical Corp. reported a 64% revenue increase for Q3 2024 compared to the same quarter last year, reaching $2.83 million. The company is transitioning to a traditional medtech business model with improved reimbursement for its TULSA procedure, aiming for broader market access. However, they reported a net loss of $9.4 million, which has increased from the previous year, alongside a significant rise in operating expenses. Profound anticipates full-year 2024 revenue growth of 53% to 67%, with positive developments in ongoing clinical trials and leadership changes.
Read more →PROF▲ +11.6%on this newsshared move
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
Profound Medical Corp. announced that the TULSA procedure has been assigned a Level 7 reimbursement under the U.S. CMS Outpatient Prospective Payment System, effective January 1, 2025. This decision introduces a Category 1 CPT code for TULSA, allowing for different billing structures depending on the number of physicians involved. Notably, the payment rates for the TULSA procedure are significantly higher than those for other common prostate treatments. This development positions TULSA favorably among treatment options for prostate disease and emphasizes its unique value proposition in the market.
Read more →PROFProfound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
Profound Medical Corp. will disclose its third quarter 2024 financial results on November 7, 2024, after market close. Following the announcement, the company's management will host a conference call to review the results and discuss business developments. Profound is known for its incision-free therapies for disease treatment, notably through its TULSA-PRO® and Sonalleve® systems. The conference call will be accessible through the company's website and a live registration link.
Read more →PROFProfound Medical Appoints Tom Tamberrino as Chief Commercial Officer
Profound Medical Corp. has appointed Tom Tamberrino as its new Chief Commercial Officer. This decision is strategic, coinciding with the upcoming implementation of permanent CPT Category 1 codes for its TULSA technology in 2025. Tamberrino, who has a successful track record in sales and marketing within the medical sector, previously worked at NOVADAQ Technologies. He is expected to leverage his experience to enhance awareness and adoption of Profound's innovative incision-free therapies for prostate disease.
Read more →PROFProfound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA
Profound Medical Corp. hosted its second 'PRO-Talk Live!' event in Las Vegas on September 14, 2024, featuring 70 physicians, including current and potential users of the TULSA-PRO technology. The event focused on presentations from key opinion leaders sharing insights on TULSA-PRO's versatility in treating prostate diseases. Notable global medtech leaders Siemens Healthineers and Cook Medical also participated, discussing their joint vision to develop an integrated MR solution for prostate treatment. Profound's CEO emphasized the importance of physician education in driving adoption and expanding access to TULSA.
Read more →PROFProfound Medical to Participate in Lake Street’s Best Ideas Growth Conference
Profound Medical Corp. announced its participation in the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024, in New York City. The company's management will engage in one-on-one meetings with investors, although no webcast will be available for the event. Profound Medical focuses on developing incision-free therapies for treating diseased tissue, particularly their TULSA-PRO technology aimed at prostate disease treatment, and Sonalleve, which addresses uterine fibroids and related conditions.
Read more →PROFProfound Medical Announces Second Quarter 2024 Financial Results
Profound Medical Corp. announced its financial results for Q2 2024, reporting a revenue increase of 39% to $2.23 million compared to the previous year. The company has grown its installed base of TULSA-PRO systems and continues to expect substantial revenue growth for the full year. Despite these positive developments, Profound recorded a net loss of $6.9 million for the quarter. The company is also focusing on expanding its TULSA technology and has received FDA clearance for a new AI module.
Read more →PROFProfound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
Profound Medical Corp. will release its financial outcomes for the second quarter of 2024 on August 8, 2024, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and business developments. Profound Medical focuses on innovative medical devices for tissue ablation, including its TULSA-PRO and Sonalleve platforms, which are aiming for diverse treatment applications.
Read more →PROFProfound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
Profound Medical Corp. announced that the U.S. Centers for Medicare and Medicaid Services has proposed a Category 1 CPT code for the TULSA procedure, effective January 1, 2025. This new coding includes three physician codes based on the number of physicians involved, facilitating flexible treatment delivery across multiple settings. The proposed facility and physician fees suggest robust reimbursement rates, significantly impacting the economic feasibility of the TULSA procedure, although it may limit post-operative reimbursement compared to other treatments.
Read more →PROFProfound Medical Annual General Meeting of Shareholders Voting Results
Profound Medical Corp. announced the results of its Annual General Meeting of Shareholders held on May 15, 2024. A total of 15,336,388 common shares were represented, approving all matters presented. The election of all six board nominees received strong vote support, and PricewaterhouseCoopers LLP was retained as the auditor for the company. Detailed voting results will be made available on the company's profile.
Read more →PROF▲ +7.3%on this newsshared move
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Corp. has obtained FDA 510(k) clearance for its Contouring Assistant AI module, part of the TULSA-AI suite. This module enhances the TULSA-PRO® system by improving prostate segmentation accuracy and reducing treatment time for urologists. Clinical studies demonstrated that the use of the module yields results comparable to expert radiologists while increasing efficiency. The company is also planning to develop additional AI modules to further enhance treatment capabilities.
Read more →PROF▲ +13.6%on this newsshared move
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
Profound Medical Corp. announced its financial results for Q1 2024, reporting revenues of approximately $1.91 million, an increase from the previous year. The company also provided revenue guidance for the full year, projecting growth between 53% to 67%. Notably, the installed base of TULSA-PRO® systems increased, and new reimbursement codes are anticipated. However, the net loss remains significant, with operating expenses rising above revenue growth, reflecting challenges in financial management.
Read more →PROFGrowing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical's TULSA procedure is gaining traction as a promising treatment for prostate diseases, backed by an increasing body of clinical evidence. The company is optimistic about its potential to become a mainstream option in the healthcare landscape. This development is expected to enhance the treatment spectrum for prostate conditions significantly.
Read more →PROFProfound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Profound Medical Corp. will announce its first quarter 2024 financial results on May 9, 2024, after market close. Following the announcement, a conference call is scheduled at 4:30 p.m. ET to discuss the results and any relevant business developments. The company highlights its TULSA-PRO and Sonalleve technologies, both of which are designed to provide customizable and non-invasive treatment options. Both products have received various regulatory approvals, suggesting a solid foundation for their market presence.
Read more →PROFProfound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The presentation will focus on updates regarding the company's business operations. This event highlights Profound's commitment to engaging with the investment community and showcasing its innovative medical device solutions.
Read more →PROFProfound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024, at the Metro Toronto Convention Centre. The live presentation will be accessible via the company's website. The company focuses on customizable, incision-free therapies for tissue ablation, highlighting its TULSA-PRO and Sonalleve technologies, which have received various regulatory approvals.
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Profound Medical Corp. reported its financial results for the fourth quarter and full year 2023, highlighting a significant growth in recurring revenue of 60% year-over-year for Q4 2023. The installed base of TULSA-PRO® systems reached 50, with plans to increase to 75 by 2024. Additionally, preparations for new CPT Category 1 codes for the TULSA procedure are underway for 2025, which could significantly impact business operations. However, the company also noted a net loss of approximately $8.9 million for Q4 2023, indicating ongoing financial challenges despite revenue growth.
Read more →PROFProfound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Profound Medical Corp. will participate in the Barclays 26th Annual Global Healthcare Conference on March 13, 2024. The event will feature a fireside chat that will be broadcast live and archived on the company's website. Profound Medical is known for its development of incision-free therapies, particularly the TULSA-PRO® technology for prostate treatment and the Sonalleve® therapy for uterine fibroids.
Read more →PROFProfound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
Profound Medical Corp. has announced a non-exclusive collaboration with Siemens Healthineers to market an integrated therapeutic solution combining the TULSA-PRO® system with the MAGNETOM Free.Max MRI scanner. This partnership is expected to enhance patient and physician access to the TULSA procedure, which utilizes real-time MRI guidance for precise prostate tissue ablation. The combined solution is anticipated to be available for sale in 2025, supporting improved diagnosis and treatment pathways for prostate cancer. The new MRI scanner's innovative design aims to simplify operational integration in diverse healthcare settings.
Read more →PROFProfound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
Profound Medical Corp. has announced the pricing of its public offering of 2,666,667 common shares at US$7.50 each. This offering is expected to generate gross proceeds of approximately US$20 million before expenses. The offering is led by institutional investors focused on healthcare.
Read more →PROFProfound Medical 2023 Virtual Analyst & Investor Day Agenda
Profound Medical Corp. has announced the agenda for its upcoming Analyst & Investor Day on October 13, 2023. The event will take place from 1:00 p.m. to approximately 3:30 p.m. Eastern Time. This initiative reflects the company's ongoing efforts to connect with stakeholders and share insights about its incision-free therapies.
Read more →PROFProfound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost
Profound Medical has announced that it has received 510(k) clearance from the U.S. FDA for its TULSA-PRO® Thermal Boost system. This clearance allows the company to market the device, which is expected to improve treatment options for patients. The approval represents a significant advancement in the company's product offerings.
Read more →PROFSave the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13
Profound Medical Corp. will host a virtual Analyst & Investor Day on October 13, 2023. The event is scheduled to take place from 1:00 p.m. to approximately 3:30 p.m. Eastern Time. This initiative aims to provide insights into the company's customizable, incision-free therapies for ablation.
Read more →PROFProfound Medical Announces At-the-Market Offering of up to US$30,000,000
Profound Medical Corp. has launched an at-the-market equity program, enabling the issuance and sale of up to US$30 million in common shares. This initiative aims to enhance the company's financial flexibility and support its growth strategies. The program will be executed through designated securities dealers acting as agents.
Read more →PROFProfound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases
Profound Medical Corp. has announced that the American Medical Association has established three new CPT Category 1 codes for the TULSA procedure, which is used for MRI-monitored transurethral ultrasound ablation of prostate tissue. This development, supported by various physician specialty societies, is expected to improve reimbursement for the TULSA-PRO system. The new codes signify a significant advancement for the company's technology in treating prostate diseases.
Read more →PROFTULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting
Profound Medical Corp. announced that the TULSA Procedure was featured in the scientific program at the American Urological Association 2023 Annual Meeting. This event highlights advancements in urological treatments and showcases innovative procedures. The company's participation underscores its commitment to improving patient care through novel technologies.
Read more →PROFProfound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present an update on its business at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023. The event will take place at the Metro Toronto Convention Centre. This participation highlights the company's commitment to engaging with the investment community.
Read more →PROFFour Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer
Profound Medical announced positive four-year follow-up data from its TACT pivotal clinical trial, showcasing durable treatment effects of TULSA-PRO® for men with localized prostate cancer. The results were presented by Dr. Laurence Klotz at the FOCAL 2022 Conference in Los Angeles. This marks a significant advancement in the company's efforts to provide effective, incision-free therapies.
Read more →PROFProfound Medical Provides TULSA-PRO® Reimbursement Update
Profound Medical Corp. has announced a reimbursement update for its TULSA-PRO system, which is designed for Transurethral Ultrasound Ablation (TULSA). This update signifies a positive step towards enhancing the accessibility of their innovative, incision-free therapies for treating diseased tissue. The company continues to focus on expanding its market presence in the U.S.
Read more →PROFProfound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present at the Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022. The presentation will focus on the company's advancements in customizable, incision-free therapies for tissue ablation. This engagement highlights the company's commitment to investor relations and market presence.
Read more →PROFProfound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical has announced that its TULSA-PRO® system is now compatible with GE Healthcare's 3T MRI scanners. This advancement is expected to enhance the system's functionality and broaden its application in clinical settings. The compatibility aims to improve patient outcomes by leveraging advanced imaging technology.
Read more →PROFProfound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. has announced its participation in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference. The event is scheduled to take place from February 15 to 17, 2022. This participation highlights the company's commitment to advancing its incision-free therapies for tissue ablation.
Read more →PROFTULSA-PRO® Was Front and Center at AUA2022
Profound's innovative TULSA-PRO technology was prominently featured at AUA2022. A semi-live procedure was conducted by Dr. Kenneth A. Goldberg from UT Southwestern during the plenary session. This event showcased the advancements in prostate treatment and highlighted the technology's potential impact on patient care.
Read more →PROFKenneth Knudson Joins Profound Medical as Chief Commercial Officer
Profound Medical Corp. has appointed Kenneth Knudson as Chief Commercial Officer. Knudson, a veteran in the global medical device industry, will oversee the company's sales, marketing, and reimbursement efforts. This strategic appointment aims to enhance Profound's market presence and drive growth in its innovative, incision-free therapies.
Read more →PROFProfound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®
Profound Medical Corp. has entered into a multi-center commercial agreement with Akumin Inc. for its TULSA-PRO® technology. This partnership aims to enhance the availability of incision-free therapies for tissue ablation across multiple imaging centers in the U.S. The collaboration is expected to strengthen Profound's market presence.
Read more →PROFProfound Medical Receives FDA HDE Approval for Sonalleve®
Profound Medical Corp. has announced that its Sonalleve® device has received FDA approval under a Humanitarian Device Exemption for treating osteoid osteoma. This approval represents a significant advancement for the company and provides a new therapeutic option for patients with this condition. The approval is expected to enhance Profound's market presence.
Read more →PROFProfound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO®
Profound Medical Corp. has signed a co-development agreement with GE Healthcare to enhance access to its TULSA-PRO® system. This collaboration aims to expand the availability of Profound's incision-free therapies, which utilize advanced MRI and thermal ultrasound technology. The partnership is expected to bolster the company's market presence and improve patient outcomes.
Read more →PROFProfound Medical to Participate in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
Profound Medical Corp. will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on April 21, 2021. The presentation will provide updates on the company's business and its customizable, incision-free therapies for tissue ablation. This event highlights Profound's commitment to investor relations and market engagement.
Read more →PROFProfound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO®
Profound Medical Corp. has signed a groundbreaking multi-center commercial agreement with RadNet, marking the first of its kind in the U.S. for its TULSA-PRO® system. This partnership aims to expand the availability of Profound's innovative, incision-free therapies that utilize real-time MRI and thermal ultrasound for tissue ablation. The collaboration is expected to enhance patient access to advanced imaging services.
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update
Profound Medical Corp. has announced preliminary unaudited revenues for Q4 and the full year of 2019, indicating positive growth. The company also provided an update on its commercialization efforts for TULSA-PRO® in the U.S. This announcement precedes the 38th Annual J.P. Morgan Healthcare Conference, where further details will be shared.
Read more →PROFProfound Medical Announces Health Canada Approval of TULSA-PRO®
Profound Medical Corp. has received Health Canada approval for its TULSA-PRO® system, designed for the radiation-free ablation of low to intermediate risk organ-confined prostate cancer. This innovative system combines real-time MRI, thermal ultrasound, and closed-loop temperature feedback control, marking a significant advancement in prostate cancer treatment.
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. will announce its fourth quarter and full year 2023 financial results on March 7, 2024, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and business developments. The company is known for its incision-free therapies, including the TULSA-PRO technology and Sonalleve platform, both aimed at treating various medical conditions. Both devices have received multiple regulatory approvals, enhancing their market potential and credibility.
Read more →PROFProfound Medical Announces Non-Brokered Private Placement
Profound Medical Corp. announced a non-brokered private placement, generating gross proceeds of approximately US$2.94 million through subscription agreements with existing Canadian institutional investors. The company plans to issue 391,667 common shares at a price of US$7.50 each. Proceeds will be utilized to continue the commercialization of its TULSA-PRO system in the U.S. and the Sonalleve system globally. The closing of this placement is anticipated around January 17, 2024, subject to standard closing conditions.
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
Profound Medical Corp. has announced preliminary unaudited revenues for Q4 and full year 2023, projecting between $1.9 to $2.0 million for Q4 and around $7.1 to $7.2 million for the full year. The growth in revenue is attributed primarily to sales of TULSA-PRO consumables and services, signaling a successful commercialization strategy. The company also highlighted its progress in the adoption of TULSA-PRO at major cancer hospitals across the U.S. as they prepare for significant revenue opportunities with upcoming changes in reimbursement codes.
Read more →PROF▼ -8.5%on this news
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares TORONTO, ON (
Profound Medical Corp. has announced the pricing of a public offering of 2,666,667 common shares at US$7.50 each, aiming to raise US$20 million. The proceeds will support the commercialization of its TULSA-PRO and Sonalleve systems, which are innovative medical devices. The Offering is expected to close on January 2, 2024, pending customary conditions and regulatory approvals. However, there is uncertainty regarding the completion timeline and the shares will not be available to Canadian residents.
Read more →PROF▼ -8.5%on this news
Profound Medical Announces Proposed Public Offering of Common Shares TORONTO, ON (
Profound Medical Corp. has announced its plan for a public offering of common shares in the U.S. to fund the commercialization of its TULSA-PRO and Sonalleve medical technologies. The offering's pricing and total size will be based on market conditions and finalized upon entering an underwriting agreement. The company intends to utilize the proceeds for continued product development and working capital. However, the completion of the offering is subject to customary conditions and regulatory approvals, creating some uncertainty.
Read more →PROFProfound Medical to Participate in the Stifel 2023 Healthcare Conference
Profound Medical Corp. announced its participation in the Stifel 2023 Healthcare Conference, where management will present updates on the company’s business. The conference is set for November 15, 2023, at 8:35 a.m. Eastern Time in New York City. Profound Medical is known for its incision-free therapies, including the TULSA-PRO technology for prostate ablation and the Sonalleve platform for treating uterine fibroids. The presentation will be accessible via live broadcast and archived on the company's website.
Read more →PROFProfound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting
Profound Medical Corp. announced the extension of the HCPCS C code, C9734, for its TULSA procedure in Ambulatory Surgical Centers. This decision by CMS will take effect on January 1, 2024, allowing more facilities to use this innovative approach in prostate tissue ablation. The TULSA-PRO® system has been assigned device-intensive status, indicating its significance in outpatient settings. With permanent CPT codes set for 2025, this extension is a pivotal move for accessibility and innovation in prostate treatments.
Read more →PROF▲ +8%on this newsshared move
Profound Medical Announces Third Quarter 2023 Financial Results
Profound Medical Corp. reported its financial results for the third quarter of 2023, showcasing a recurring revenue growth of 40% compared to the same period last year. The company achieved FDA clearance for its TULSA AI Thermal Boost module, which is posited to enhance cancer treatment outcomes. Despite a decrease in overall revenue and an increase in net loss, the firm maintained a solid cash position of approximately $33.6 million. The third quarter also highlighted a decline in operating expenses, demonstrating improved cost management strategies.
Read more →PROFProfound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
Profound Medical Corp. will announce its third quarter 2023 financial results on November 2, 2023, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. The company is recognized for its customizable, incision-free therapies, including TULSA-PRO® and Sonalleve®, both of which are commercially available. These innovations aim to address various medical conditions while prioritizing patient safety and functional preservation.
Read more →PROFProfound Medical 2023 Virtual Analyst & Investor Day Agenda
Profound Medical Corp. has announced the agenda for its Analyst & Investor Day, scheduled for October 13, 2023. The event will feature key presentations on the TULSA-PRO® technology, including insights from experienced surgeons and patient testimonials. The company's management will also provide updates regarding clinical and commercial developments. Attendees are required to preregister for the live interactive event, which will be available for later viewing on the company's website.
Read more →PROFProfound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost
Profound Medical Corp. has received FDA 510(k) clearance for its Thermal Boost module, designed to enhance the TULSA-PRO system used in prostate ablation. This module allows surgeons to increase ablation temperatures in specific areas, potentially leading to better treatment outcomes. The Thermal Boost is already CE-Marked and has been beneficial in European treatments, showing positive results in a majority of cases. Profound aims to develop additional modules under the TULSA AI branding to further improve treatment customization and effectiveness.
Read more →PROFProfound Medical to Participate in the 2023 Cantor Global Healthcare Conference
Profound Medical Corp. will present an update on its business at the 2023 Cantor Global Healthcare Conference on September 26, 2023. The company focuses on customizable medical devices, particularly its TULSA-PRO® technology for prostate ablation and Sonalleve® platform for treating uterine fibroids and palliative pain. Both technologies have received various regulatory approvals, highlighting their potential impact in their respective treatment markets. The presentation will be available for live streaming on the company's website.
Read more →PROFProfound Medical Announces At-the-Market Offering of up to US$30,000,000 TORONTO, ON (
Profound Medical Corp. announced the creation of an at-the-market equity program, allowing it to raise up to $30 million through the sale of common shares. The funds will be primarily used to further commercialize their TULSA-PRO system in the U.S. and support the development of their Sonalleve system globally. The company received conditional approval from the Toronto Stock Exchange for the new shares, although actual proceeds may vary based on market conditions and sale timing.
Read more →PROFProfound Medical Announces Second Quarter 2023 Financial Results
Profound Medical Corp. reported its financial results for the second quarter of 2023, showing a revenue of approximately $1.6 million, down from $2.0 million in the same quarter of the previous year. The quarter was marked by a significant milestone with the American Medical Association establishing new CPT Category 1 codes for the TULSA procedure, which is expected to enhance its adoption. Notably, recurring revenue saw a 38% increase compared to Q2-2022. However, the company experienced a higher net loss of $7.4 million, highlighting ongoing financial challenges despite improvements in managing expenses.
Read more →PROFProfound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow
Profound Medical Corp. will announce its second quarter 2023 financial results after market close on August 9, 2023. Following the announcement, company management will host a conference call at 4:30 p.m. ET to review the results and discuss any business developments that occurred during the quarter. Profound's advancements in medical devices, like TULSA-PRO and Sonalleve, continue to show promise for various therapeutic applications.
Read more →PROF▲ +10.3%on this news· ran to +23% by day 3
Profound Medical Announces New CPT Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases
Profound Medical Corp. announced that the American Medical Association has established three new CPT Category 1 codes for its TULSA-PRO system, designed for MRI-monitored transurethral ultrasound ablation of prostate tissue. These codes will facilitate broader adoption of the TULSA procedure by allowing more flexible reimbursement arrangements for physicians. The codes will be effective from January 1, 2025, enhancing support for medical providers treating prostate diseases. The move represents significant progress in making innovative prostate treatments more accessible in the U.S.
Read more →PROFProfound Medical to Participate in A.G.P.’s Virtual Healthcare Conference
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced its participation in A.G.P.'s Virtual Healthcare Conference on May 24, 2023. The event will include one-on-one meetings with investors, although no webcast will be available due to the conference format. Profound Medical specializes in customizable, incision-free therapies for tissue ablation, including its CE marked TULSA-PRO for prostate treatments and Sonalleve for uterine fibroids. These technologies are designed to improve patient outcomes while minimizing invasive procedures.
Read more →PROFProfound Medical Annual and Special Meeting of Shareholders Voting Results
Profound Medical Corp. held its Annual and Special Meeting of Shareholders, where all matters presented were approved. Key outcomes included the successful election of six directors with high approval rates and the appointment of PricewaterhouseCoopers LLP as the company's auditor. This event reflects strong shareholder engagement, with over 63% of common shares represented at the meeting. The company continues to advance its medical technologies, including TULSA-PRO and Sonalleve, aimed at treating prostate ailments and uterine fibroids, respectively.
Read more →PROFProfound Medical Announces First Quarter 2023 Financial Results
Profound Medical Corp. announced its financial results for the first quarter of 2023, reporting a revenue increase of 36% year-over-year to approximately $1.9 million. The company noted positive clinical feedback related to its TULSA technology, which positions it favorably in the prostate treatment market. Additionally, it reported a reduced net loss of approximately $6.8 million compared to the previous year. However, the increase in total operating expenses and R&D costs highlights ongoing financial pressures.
Read more →PROF▲ +5.6%on this news
EXECUTION COPY INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSE
Profound Medical Inc. has excluded certain confidential information from public disclosure, claiming it is not material and could cause competitive harm. The details pertain to a credit agreement among the company and its subsidiaries with the Canadian Imperial Bank of Commerce for a maximum credit amount of up to $10,000,000. While this funding could support operational needs, the lack of transparency may lead to concerns regarding investor confidence and competitive positioning in the market.
Read more →PROF▲ +6.1%on this news
Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow
Profound Medical Corp. will announce its first quarter 2023 financial results on May 10, 2023, after market close. Following the announcement, management will conduct a conference call at 4:30 p.m. ET to provide insights into the results and discuss business developments. The company specializes in incision-free therapies for diseased tissue and is actively marketing two main technologies, TULSA-PRO® and Sonalleve®, which are CE marked and have necessary approvals from regulators.
Read more →PROF▲ +6.1%on this news
Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present at the Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023, providing updates on its business operations. The company specializes in incision-free therapies and is commercializing notable technologies such as TULSA-PRO® and Sonalleve®. The presentation will be available via live broadcast and archived on their website for interested stakeholders.
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2022 Financial Results
Profound Medical Corp. reported its financial results for the fourth quarter and full year 2022, highlighting a 26% increase in quarterly revenue from recurring sources. The company's TULSA business has become a key driver for revenue growth, although one-time capital sales remain negatively impacted by ongoing COVID-19 challenges. Profound's CEO expressed optimism about the future, particularly with the upcoming consideration of a CPT Category 1 application that could enhance TULSA adoption. Despite the positive revenue figures, the company recorded substantial net losses and a goodwill impairment during the period.
Read more →PROFProfound Medical to Present at the 43rd Annual Cowen Health Care Conference
Profound Medical Corp. will be presenting at the 43rd Annual Cowen Health Care Conference on March 8, 2023, showcasing their innovative medical technologies. CEO Arun Menawat is expected to provide an update on the company's business strategies and products, including the TULSA-PRO and Sonalleve platforms. These technologies aim to deliver customizable, incision-free therapies for various medical conditions. The presentation will be available for live streaming and on-demand viewing via Profound's website.
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. is scheduled to announce its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. A conference call will follow to review these results and discuss business developments during the reporting period. The company continues to promote its advanced technologies, TULSA-PRO® and Sonalleve®, both of which have gained regulatory approvals for their respective indications in medical treatments.
Read more →PROFProfound Medical to Present at the 2022 Jefferies London Healthcare Conference
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced t
Read more →PROFProfound Medical Announces Third Quarter 2022 Financial Results
TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fi
Read more →PROFProfound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
Read more →PROFProfound Medical Announces Changes to its Commercial Organization to Support Continued Growth
TORONTO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced
Read more →PROF▼ -14.1%on this news
Profound Medical to Participate in September Investor Conferences
TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced
Read more →PROF▼ -5.3%on this news· ran to -19% by day 3shared move
Profound Medical Provides TULSA-PRO Reimbursement Update
TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a
Read more →PROFProfound Medical Announces Second Quarter 2022 Financial Results
TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fi
Read more →PROFProfound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow
TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
Read more →PROFProfound Medical to Participate in the Cowen 7th Annual FutureHealth Conference
TORONTO, June 16, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced t
Read more →PROF▲ +6.4%on this news
Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference
TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced t
Read more →PROFProfound Medical Clarifies Recent Insider Buying
TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Compa
Read more →PROFPROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 18, 2022 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 8, 2022 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEE
PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS HELD ON MAY 18, 2022 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 8, 2022 OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the "Meeting"
Read more →PROF▼ -7.6%on this news
Profound Medical Announces First Quarter 2022 Financial Results
TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fin
Read more →PROFProfound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced
Read more →PROF▼ -8.5%on this news
Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce it
Read more →PROF▼ -6.9%on this news· ran to -18% by day 3
Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported f
Read more →PROFProfound Medical to Participate in March Investor Conferences
TORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced
Read more →PROFProfound Medical’s TULSA-PRO Now Compatible with GE Healthcare’s 3T MRI Scanners
TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed
Read more →PROF▼ -5.2%on this news
Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow
TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
Read more →PROFProfound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced t
Read more →PROFProfound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced t
Read more →PROFProfound Medical Announces Third Quarter 2021 Financial Results
TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fi
Read more →PROFProfound Medical to Participate in November Virtual Investor Conferences
TORONTO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today t
Read more →PROFProfound Medical to Release Third Quarter 2021 Financial Results on November 4 – Conference Call to Follow
TORONTO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
Read more →PROFProfound Medical to Participate in September Virtual Investor Conferences
TORONTO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today t
Read more →PROFProfound Medical Announces Second Quarter 2021 Financial Results
TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fi
Read more →PROFProfound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference
TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today t
Read more →PROF▼ -6.2%on this news
Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow
TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
Read more →PROFProfound Medical to Participate in June Investor Conferences
TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today
Read more →PROFProfound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes
TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the “Meeting”). A total of 11,810,287 common shares, repr
Read more →PROFProfound Medical Announces First Quarter 2021 Financial Results
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fin
Read more →PROFProfound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO
TORONTO, May 06, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced th
Read more →PROFProfound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow
TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce it
Read more →PROFProfound Medical to Participate in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today
Read more →PROFProfound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors
TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment o
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2020 Financial Results
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported f
Read more →PROFProfound Medical to Participate in March Virtual Investor Conferences
TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management wi
Read more →PROFProfound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management wi
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2020 Financial Results on March 2 – Conference Call to Follow
TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter a
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Revenues
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudi
Read more →PROFProfound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO
TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Receives FDA HDE Approval for Sonalleve
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment o
Read more →PROFProfound Medical Announces Changes to its Board of Directors
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Participate in November Virtual Investor Healthcare Conferences
TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Third Quarter 2020 Financial Results
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Release Third Quarter 2020 Financial Results on November 5 – Conference Call to Follow
TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Present at the Cantor Virtual Global Healthcare Conference
TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical Present at the Canaccord Genuity 40th Annual Growth Conference
TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Second Quarter 2020 Financial Results
TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Release Second Quarter 2020 Financial Results on August 6 – Conference Call to Follow
TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Closing of Offering
TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”)
Read more →PROFProfound Medical Announces Pricing of Offering of Common Shares
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,758,621 common shares of the Company (the “Common Shares”), at a pri
Read more →PROFExecution Version PROFOUND MEDICAL CORP. 2,758,621 Common Shares
PROFOUND MEDICAL CORP. 2,758,621 Common Shares UNDERWRITING AGREEMENT COWEN AND COMPANY, LLC As representatives of the several underwriters New York, New York 10022 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Raymond James Ltd. 40 King S
Read more →PROFProfound Medical Announces Proposed Offering of Common Shares
TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated
Read more →PROFNASDAQ: PROF TSX: PRN Corporate Presentation |
NASDAQ: PROF TSX: PRN Corporate Presentation | July 15, 2020 - Offering of Common Shares 2020 Profound Medical Corp. A final base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory
Read more →PROFProfound Medical Announces First Quarter 2020 Financial Results
Profound Medical Announces First Quarter 2020 Financial Results TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), the only company to provide customizable, incision-free therapies which combine real-time Magnet
Read more →PROFProfound Medical to Release First Quarter 2020 Financial Results on May 7 – Conference Call to Follow
TORONTO, April 16, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2019 Financial Results
TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal
Read more →PROFProfound Medical Participate in March Investor Healthcare Conferences
TORONTO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal u
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2019 Financial Results on March 3 – Conference Call to Follow
TORONTO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal u
Read more →PROFProfound Medical Retires Bank Debt Ahead of Schedule
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal u
Read more →PROFExecution Version PROFOUND MEDICAL CORP. 2,950,000 Common Shares
PROFOUND MEDICAL CORP. 2,950,000 Common Shares UNDERWRITING AGREEMENT COWEN AND COMPANY, LLC As representative of the several underwriters 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Profound Medical Corp., a corporation organized under the laws o
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO U.S. Commercialization Update
TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal u
Read more →PROFProfound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO
TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal u
Read more →PROFProfound Medical to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
TORONTO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Health Canada Approval of TULSA-PRO
TORONTO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Third Quarter 2019 Financial Results
TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound to Participate in November Investor Healthcare Conferences
TORONTO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces Nasdaq Listing
TORONTO, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMD) (“Profound” or the “Company”) today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has certified the Company’s common shares for listing on the Nasdaq Capital Market. Profound’s common
Read more →PROFProfound Medical to Release Third Quarter 2019 Financial Results on November 7 – Conference Call to Follow
TORONTO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRMFD) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Corp. Announces Share Consolidation in Connection With Proposed Nasdaq Listing
TORONTO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; OTCQX: PRFMF) (“Profound” or the “Company”) is pleased to announce that today it implemented a consolidation (the “Consolidation”) of its issued and outstanding common shares (“Common Shares”) on the bas
Read more →PROFProfound Medical Proposes New MJDS Registration for its Proposed U.S. Listing
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it proposes to file a new registration statement unde
Read more →PROFProfound Medical Announces Closing of Offerings
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced offering of un
Read more →PROFProfound Medical Announces Pricing of Offerings
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce the pricing of its previously-announced marketed offering
Read more →PROFProfound Medical Announces Proposed Offerings of Units
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it intends to file a prospectus supplement to its sho
Read more →PROFProfound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO
TORONTO, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market TULSA-PRO® for ablation of prostate tissue. TUL
Read more →PROFProfound Medical Announces Second Quarter 2019 Financial Results
TORONTO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Present at the Canaccord Genuity 39th Annual Growth Conference
TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical to Release Second Quarter 2019 Financial Results on August 14 – Conference Call to Follow
TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Sells First TULSA-PRO System in Japan
TORONTO, July 09, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop
Read more →PROFProfound Medical Announces First Quarter 2019 Financial Results
- Receives Notification of FDA Acceptance of 510(k) Application Filing for TULSA-PRO® - TORONTO, May 06, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which
Read more →PROFProfound Medical to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 23, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical to Release First Quarter 2019 Financial Results on May 6 – Conference Call to Follow
TORONTO, April 17, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical Announces First-of-its-Kind TULSA-PRO Installation
TORONTO, April 16, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical Analyst & Investor Day Agenda
TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO in Patients with Prostate Cancer
TORONTO, April 04, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loo
Read more →PROFProfound Medical Announces Fourth Quarter and Full Year 2018 Financial Results
TORONTO, March 07, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abl
Read more →PROFProfound Medical to Present at the Cowen and Company 39th Annual Health Care Conference
TORONTO, March 05, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incisi
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2018 Financial Results on March 7 – Conference Call to Follow
TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incisio
Read more →PROFProfound Medical to Participate in the 2019 BTIG MedTech, Life Science & Diagnostic Tools Conference
TORONTO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incisio
Read more →PROFProfound Medical Announces Preliminary Unaudited Fourth Quarter 2018 Revenues
TORONTO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incisio
Read more →PROFProfound Medical Announces Changes to Commercial Organization
TORONTO, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical Announces Third Quarter 2018 Financial Results
Prepares for First Sonalleve® Shipment to China TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance
Read more →PROFProfound Medical to Present at the Stifel 2018 Healthcare Conference
TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical to Release Third Quarter 2018 Financial Results on November 8 – Conference Call to Follow
TORONTO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical Files Preliminary Base Shelf Prospectus
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES TORONTO, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) announced today that it has filed and obtained a receipt for a preliminary short
Read more →PROFProfound Medical Announces Second Quarter 2018 Financial Results
TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical to Release Second Quarter 2018 Financial Results on August 14 – Conference Call to Follow
TORONTO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and abla
Read more →PROFProfound Medical Announces Term Loan Agreement with CIBC Innovation Banking
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSX:PRN) (OTCQX:PRFMF) today announced that it has entered into a term loan agreement (the “Agreement”) with the CIBC Innovation Banking (“CIBC”), which provides Profound with up to $
Read more →PROFProfound Medical Corp. Announces Graduation to Toronto Stock Exchange
TORONTO, July 11, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and a
Read more →PROFProfound Medical Announces Annual Meeting of Shareholders Voting Results; Welcomes Two Industry Veterans as Independent Directors to its Board
TORONTO, June 14, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV: PRN) (OTCQX:PRFMF) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held today. A total of 55,264,907 co
Read more →PROFProfound Medical Corp. Announces First Quarter 2018 Financial Results
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ab
Read more →PROFProfound Medical Corp. Announces Chinese Food and Drug Administration Approval for Sonalleve
TORONTO, May 09, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ab
Read more →PROFProfound Medical to Release First Quarter 2018 Financial Results on May 10, 2018 – Conference Call to Follow
TORONTO, May 02, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (ins
Read more →PROFProfound Medical Further Strengthens Management Team with Appointment of Aaron Davidson as Chief Financial Officer and Senior Vice-President of Corporate Development
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ab
Read more →PROFProfound Medical to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and
Read more →PROFProfound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results
TORONTO, March 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and
Read more →PROFProfound Medical Corp. Announces Closing of Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. MISSISSAUGA, Ontario, March 20, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2017 Financial Results on March 26, 2018 – Conference Call to Follow
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (i
Read more →PROFProfound Medical to Participate in 2018 BTIG Healthcare Conference
TORONTO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (in
Read more →PROFProfound Medical Corp. Announces Completion of Patient Enrollment in TACT Pivotal Clinical Trial
TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy of directional (in
Read more →PROFProfound Medical Corp. Announces Preliminary Fourth Quarter 2017 Revenue and Provides Progress Update on TACT Pivotal Trial Patient Enrollment
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. to Present at the 29th Annual Piper Jaffray Healthcare Conference
TORONTO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. Announces Third Quarter 2017 Financial Results
TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and a
Read more →PROFProfound Medical Corp. Announces Expanded Clinical Use of TULSA-PRO in Prostate Care to Include BPH
TORONTO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. to Present at the 2017 Canaccord Genuity Medical Technologies & Diagnostics Forum
TORONTO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. to Release Third Quarter 2017 Financial Results on November 7, 2017 – Conference Call to Follow
TORONTO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. Announces Closing of $10 Million “Bought Deal” Financing
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) is pleased to announce the closing of its previously announced bought deal financing
Read more →PROFProfound Medical Corp. Announces $10 Million “Bought Deal” Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound”) is pleased to announce that it has entered into an agreement with a syndica
Read more →PROFProfound Medical Announces Second Quarter 2017 Financial Results
TORONTO, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and ablation power of directio
Read more →PROFProfound Medical Corp. to Release Second Quarter 2017 Financial Results on August 23, 2017 – Conference Call to Follow
TORONTO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of direct
Read more →PROFProfound Medical Corp. Completes Acquisition of Royal Philips’ Sonalleve MR-HIFU Business
TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- With reference to its press release dated June 30, 2017, Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that all closing conditions have been satisfied and it has completed the acquisition of Royal Philips’
Read more →PROFProfound Medical Corp. Announces Definitive Agreement with Royal Philips to Expand Collaboration and Acquire Sonalleve MR-HIFU Business
TORONTO, June 30, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that it has entered into a definitive agreement (the “Agreement”) to expand the existing collaboration between the two companies and acquire Royal Philips’ (NYS
Read more →PROFProfound Medical Corp. Announces Annual Meeting of Shareholders Voting Results
TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV:PRN) (OTCQX:PRFMF) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held yesterday. A total of 30,091,325 c
Read more →PROFProfound Medical Corp. Announces First Quarter 2017 Financial Results
TORONTO, May 09, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today reported financial results for the three months ended March 31, 2017. All amounts, unless spe
Read more →PROFProfound Medical to Present at the CIBC Technology & Innovation Conference 5.0
TORONTO, May 03, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) “Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that its CEO, Arun Menawat, will present an update on the Company's business at th
Read more →PROFProfound Medical Corp. to Release First Quarter 2017 Financial Results on May 9, 2017 – Conference Call to Follow
TORONTO, April 25, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce its first quarter 2017 financial results after market close on Tuesday, May 9, 20
Read more →PROFProfound Medical Corp. Obtains DTC Eligibility for its Common Shares in the U.S.
TORONTO, April 18, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, announced today that it has secured Depository Trust Company (“DTC”) eligibility for its common
Read more →PROFProfound Medical Corp. Announces First Paid Procedure Using TULSA-PRO System
TORONTO, March 27, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that the first TULSA-PRO® patient paid procedure has been successfully conducted
Read more →PROFProfound Medical Corp. Announces Management Change
TORONTO, March 24, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today announced that Steven Plymale has resigned his position as the Company’s President and Chi
Read more →PROFProfound Medical Corp. and Philips Announce first TULSA-PRO Sale in Finland to Turku University Hospital
TORONTO, March 20, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today announced that it has successfully completed the first sale of a TULSA-PRO system in Finla
Read more →PROFProfound Medical Corp. to Begin Trading on OTCQX on March 13, 2017
TORONTO, March 09, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, is pleased to announce that its common shares will be eligible for trading on the OTCQX® Best Market under th
Read more →PROFProfound Medical Corp. Announces Fourth Quarter and Full Year 2016 Financial Results
TORONTO, March 06, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today reported financial results for the fourth quarter and full year ended December 31, 2016. All amounts, u
Read more →PROFProfound Medical Corp. to Release Fourth Quarter and Full Year 2016 Financial Results on March 6, 2017 – Conference Call to Follow
TORONTO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce its fourth quarter and full 2016 financial results after market close on Monday, March 6, 2017.
Read more →PROFProfound Medical to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
TORONTO, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that its management team is scheduled to participate in BTIG’s 2017 Medical Technology, Life S
Read more →PROFProfound Medical Announces Special Meeting of Shareholders Voting Results
TORONTO, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, is pleased to announce the results of the vote on the matters considered at its Special Meeting of Shareholder
Read more →PROFProfound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors
TORONTO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced the appointment of Kenneth Galbraith to its Board of Directors. In connection with Mr. Galbrai
Read more →PROFProfound Medical Corp. Announces Third Quarter 2016 Financial Results
TORONTO, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today reported financial results for the three months ended September 30, 2016. All amounts, unless specified
Read more →PROFProfound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSX-V:PRN) tod
Read more →PROFProfound Medical Corp. To Present at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum
TORONTO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, announced today that its CEO, Arun Menawat, will present an update on the Company's business at the Canaccord
Read more →PROFProfound Medical Corp. To Present at the Stifel 2016 Healthcare Conference
TORONTO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, announced today that its CEO, Arun Menawat, will present an update on the Company's business at the Stifel 201
Read more →PROFProfound Medical Corp. to Release Third Quarter 2016 Financial Results on November 16, 2016 – Conference Call to Follow
TORONTO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce financial results for the third quarter of 2016 after market close on Wednesday, November 16, 20
Read more →PROFProfound Medical Corp. Announces $17.4 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSX-V:PRN
Read more →PROFProfound Medical Receives Frost & Sullivan’s 2016 New Product Innovation Award
TORONTO, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, announced today that it has received Frost & Sullivan’s 2016 European Prostate Ablation Systems New Product Inn
Read more →PROFProfound Medical Corp. Announces First Patient Treated in TACT Pivotal Clinical Trial at Vanderbilt University Medical Center
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”) a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medic
Read more →PROFProfound Medical Corp. Announces Second Quarter 2016 Financial Results
TORONTO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV:PRN), an emerging medical device company focused on prostate cancer care, today reported financial results for the three months ended June 30, 2016. All amounts, unless specified
Read more →PROFProfound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy
TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer. Steven Plymal
Read more →PROFProfound Medical Corp. to Release Second Quarter 2016 Financial Results on August 18, 2016
TORONTO, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSX-V:PRN), a medical device company commercializing a unique, MR-guided ablation procedure for prostate care, will announce financial results for the quarter ended June 30, 2016 after ma
Read more →PROFProfound Medical Corp. and Philips Sell TULSA-PRO™ System to University Hospital of Cologne, Germany
TORONTO, June 21, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today announced that it and Royal Philips (“Philips”) have jointly sold a TULSA-PROTM System to University Hospi
Read more →PROFProfound Medical Corp. to hold Annual General Meeting of the Shareholders
TORONTO, June 07, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, hereby informs shareholders that its Annual General Meeting of Shareholders will be held at 10:00 a.m. (EDT) on
Read more →PROFProfound Medical Corp. and Philips Sign Sales and Marketing Agreement in MRI-guided therapy for prostate cancer care
TORONTO and AMSTERDAM, Netherlands, May 11, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN), a Toronto-based medical device company and Royal Philips (NYSE:PHG) (AEX:PHIA), a leading health technology company, today announced that they have signed a sales and marketing
Read more →PROFProfound Medical Corp. Announces First Quarter 2016 Financial Results
TORONTO, May 06, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique, MR guided ablation procedure for prostate care, today reported financial results for the three months ended March 31, 2016. Am
Read more →PROFProfound Medical Corp. to Release First Quarter 2016 Financial Results on May 6, 2016
TORONTO, April 29, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSX-V:PRN), a medical device company commercializing a unique, MR guided ablation procedure for prostate care, will announce financial results for the quarter ended March 31, 2016 after
Read more →PROFProfound Medical Corp. To Present at Upcoming Conference
TORONTO, April 29, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique, Magnetic Resonance (“MR”) guided ablation procedure for prostate care, announced that CEO Steve Plymale will present at the
Read more →PROFProfound Medical Corp. Announces World’s First Sale of TULSA-PRO for Prostate Ablation
TORONTO, April 28, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique, Magnetic Resonance (“MR”) guided ablation procedure for prostate care, today announced the first sale of its TULSA-PRO devic
Read more →PROFProfound Medical Corp., receives CE Mark Approval for TULSA-PRO™
TORONTO, April 11, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSXV:PRN), a medical device company commercializing a unique and minimally invasive therapy in prostate care, today announced that the company has received CE Mark approval for the comme
Read more →PROFProfound Medical Corp. Announces Full Year 2015 Financial Results
TORONTO, ONTARIO--(Marketwired - March 2, 2016) - Profound Medical Corp. ("Profound" or "Company") (TSX VENTURE:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, today rep
Read more →PROFProfound Medical Corp. and Siemens Enter Into Strategic Agreement to Further the Development of Prostate Cancer Care
TORONTO and ERLANGEN, Germany, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN), a Toronto-based medical device company and Siemens Healthcare today announced that they have signed a strategic collaboration agreement aimed at establishing a new Magnetic Resona
Read more →PROFProfound Medical Corp. to Release Full Year 2015 Financial Results on March 3, 2016
TORONTO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSX-V:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, will announce financia
Read more →PROFProfound Medical Corp. Announces Publication in European Urology
- TULSA-PROTM Accurately and Effectively Ablates Targeted Prostate Tissue - TORONTO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or “Company”) (TSX-V:PRN), a medical device company developing and commercializing a unique, minimally invasive technology fo
Read more →PROFProfound Medical Named 2016 Life Science Company of the Year
TORONTO, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive procedure to ablate the prostate gland in prostate cancer patients, today announced that it
Read more →PROFProfound Medical Corp. Announces Departure of CFO
TORONTO, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSXV:PRN) today announced that Mr. Shameze Rampertab has tendered his resignation as Chief Financial Officer of the Company. Mr. Rashed Dewan, the Company's Corporate Controller, will
Read more →PROFProfound Medical Corp. Announces Third Quarter 2015 Financial Results
TORONTO, Nov. 4, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, today reported financial
Read more →PROFProfound Medical Corp. to Release Third Quarter 2015 Financial Results on November 4, 2015
TORONTO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, will announce financial
Read more →PROFProfound Medical to Present at Upcoming Investor Conferences
TORONTO, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, announced that manageme
Read more →PROFProfound Medical Presents Successful 12-Month Phase I Outcomes at the European Symposium on Focused Ultrasound Therapy
TORONTO, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, is pleased to announce
Read more →PROFProfound Medical to Present 12-Month Outcomes of Phase 1 Clinical Trial at European Symposium on Focused Ultrasound Therapy
TORONTO, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, announced that an abstr
Read more →PROFProfound Medical Announces Grant of Share Options
TORONTO, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, announced today that i
Read more →Competitive Position
How PROF ranks across every disease it competes inCompetitive Position is a premium feature
See how PROF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial